Viztek, the leading provider of complete digital software and hardware diagnostic imaging solutions, will showcase its new Ultra DR software at the upcoming Association for Medical Imaging Management (AHRA) annual meeting in Washington, D.C., August 10 – 13.

A new protocol nuclear cardiologists could use to improve identification of coronary plaques involves decreasing F-18 FDG myocardial uptake to reveal more coronary detail in cardiac PET/CT. A high-fat meal prior to fasting seems to do the trick, according to a study published July 31 in the Journal of Nuclear Medicine.

For women age 75 and older, breast cancers detected by mammography were diagnosed at an earlier stage, thus reducing the rate of advanced cancers, according to a study published online August 5 in Radiology.

A disease-modifying therapy to treat Parkinson’s disease has moved through a phase I clinical trial and is set to enter a phase II study, co-sponsor the Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced Thursday.

Richard L. Wahl, MD, will be taking over as head of radiology at Washington University School of Medicine and director of the Mallinckrodt Institute of Radiology this fall, the university announced Friday.

Progenics Pharmaceuticals, a producer of oncologic drugs, most notably a prostate-specific membrane antigen targeted therapy currently in clinical trials, has announced that the company will be hosting a conference call to review second quarter 2014 financials and other topics on Friday, Aug. 8.

A new method of molecular imaging captures the dysfunction of an oncoprotein—Akt/PKB, the activation of which is tied to dismal prognoses in cancer patients. High throughput time-resolved-FRET (fluorescence resonance energy transfer) was implemented to seek out Akt/PKB activation in breast cancer patients, which could have a significant impact on not only future research, but potentially individual patient management, according to a study published in the July issue of Cancer Research.

The quantitative imaging of myocardial blood flow has been gaining momentum in recent years, as is the use of F-18 flurpiridaz, which has been shown to reveal a clear demarcation of disease in patients with CAD, according to a first-in-human quantitative imaging study published July 28 in the Journal of Nuclear Medicine.